Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
Gordon Cook(University of Leeds), María‐Victoria Mateos(Hospital Clínico San Carlos), Maren Gaudig(Janssen (Germany)), Adrían Alegre(Hospital Universitario de La Princesa), Huiling Pei(Janssen (United States)), Maria Teresa Petrucci(Policlinico Umberto I), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Matthew Streetly(King's College - North Carolina), В. В. Птушкин(City Clinical Hospital), Assem Al-Akabawi(Janssen (United Kingdom)), Wafae Iraqi(Janssen (Belgium)), Edmond S. Chan(University of British Columbia), Alessandro Corso(Aziende Socio Sanitarie Territoriale Ovest Milanese), Jon Ukropec(Genmab (United States))
Cited by 9
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719